drugset

drugset / Trial / NCT06040346

Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum

NCT06040346 ↗

Phase 2 Active not recruiting 60 enrolled Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd

NaSequentialOpen-labelTreatment

Summary

This phase 2a open-label study to assess Meplazumab in adult patients diagnosed with Plasmodium falciparum

Timeline

Start: 2024-04-26
Primary completion: 2025-08
Completion: 2025-10-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Meplazumab	Monoclonal antibody	—	Intravenous

Indications